8/11/2014 8:36:55 AM
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (“Eagle” or “the Company”) (Nasdaq: EGRX) today announced its financial results for the three-month period ended June 30, 2014. Highlights of the third quarter of 2014 and subsequent events include:
* The U.S. Food and Drug Administration (“FDA”) approved Ryanodex® (dantrolene sodium) injectable suspension indicated for the treatment of malignant hyperthermia (“MH”), along with the appropriate supportive measures. Shipments are expected to start near the end of August.
Help employers find you! Check out all the jobs and post your resume.
comments powered by